Hyperparathyroidism Market

Market Overview:

The 7 major hyperparathyroidism markets reached a value of USD 391.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 720.0 Million by 2033, exhibiting a growth rate (CAGR) of 5.65% during 2025-2035.

The hyperparathyroidism market has been comprehensively analyzed in IMARC's new report titled "Hyperparathyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Hyperparathyroidism is a medical condition characterized by the overactivity of the parathyroid glands, which are four small glands located in the neck. This disease mainly causes an imbalance in calcium levels due to the excessive production of parathyroid hormone (PTH). The common symptoms associated with the ailment include increased thirst, nausea, vomiting, loss of bone density, constipation, frequent urination, kidney stones, bone and joint pain, persistent fatigue, weakness, etc. In some cases, individuals suffering from this condition may experience changes in their mental health, such as cognitive impairment, memory problems, depression, anxiety, etc. The diagnosis of hyperparathyroidism typically involves a combination of the patient's medical history, clinical characteristics, and physical examination. Blood workups, along with kidney function tests, are also used to measure the levels of calcium, phosphorus, and PTH in the body. The healthcare professional may further conduct nuclear medicine scans, which involve the injection of a radioactive tracer into the overactive parathyroid glands to identify the presence of abnormal tissues. Additionally, a dual-energy X-ray absorptiometry (DXA) scan is recommended to assess the impact of high calcium levels on the bones.

The escalating incidences of benign tumors or adenomas on one of the parathyroid glands, leading to excessive production of PTH, are primarily driving the hyperparathyroidism market. In addition to this, the rising cases of chronic kidney diseases, which can result in diminished activation of vitamin D, reduced calcium absorption, and increased phosphate levels that stimulate the parathyroid glands, are also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as bisphosphonates, calcimimetics, estrogen replacement therapy, etc., to manage the symptoms of the ailment and decrease the risk of complications is further bolstering the market growth. Apart from this, the inflating application of parathyroidectomy, since it helps to restore the balance of calcium in the body, bringing the levels back within the normal range, is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiation therapy to preserve healthy tissues in patients who are unable to undergo surgical removal of the parathyroid glands, is expected to drive the hyperparathyroidism market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hyperparathyroidism market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hyperparathyroidism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperparathyroidism market in any manner.

Recent Development:

• In August 2024, Ascendis Pharma A/S (Nasdaq: ASND) announced that the U.S. Food & Drug Administration (FDA) had approved YORVIPATH® (palopegteriparatide ; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults.
• In January 2023, Pathalys Pharma, Inc. and Launch Therapeutics (Launch Tx) announced a collaboration to advance phase 3 clinical  trials for Upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis.

Drugs

Yorvipath (palopegteriparatide) is the FDA-approved treatment specifically developed for adults with hypoparathyroidism. This innovative therapy addresses the underlying deficiency of parathyroid hormone (PTH) by providing a sustained and physiologically regulated release of PTH, designed to restore calcium homeostasis and improve metabolic balance. Developed using the TransCon technology platform, Yorvipath offers a groundbreaking option for managing hypoparathyroidism, reducing the reliance on conventional treatments like calcium and active vitamin D supplementation.

Parsabiv (etelcalcetide) is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) who are on hemodialysis. It works by binding to and activating the calcium-sensing receptors (CaSR) on the parathyroid glands, thereby reducing parathyroid hormone (PTH) levels and subsequently lowering serum calcium and phosphorus levels. Parsabiv is administered intravenously at the end of a hemodialysis session, offering a convenient and effective option for managing SHPT in this patient population.

PLS240, also known as Upacicalcet, is an investigational intravenous calcimimetic agent under development for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease (ESKD) undergoing hemodialysis. It functions by activating calcium-sensing receptors (CaSR) on parathyroid cells, thereby reducing the secretion of parathyroid hormone (PTH) and aiding in the management of SHPT.
 

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hyperparathyroidism market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hyperparathyroidism market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current hyperparathyroidism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hyperparathyroidism market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the hyperparathyroidism market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the hyperparathyroidism market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of hyperparathyroidism across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of hyperparathyroidism by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of hyperparathyroidism by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with hyperparathyroidism across the seven major markets?
• What is the size of the hyperparathyroidism patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of hyperparathyroidism?
• What will be the growth rate of patients across the seven major markets?
   

Hyperparathyroidism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hyperparathyroidism drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperparathyroidism market?
• What are the key regulatory events related to the hyperparathyroidism market?
• What is the structure of clinical trial landscape by status related to the hyperparathyroidism market?
• What is the structure of clinical trial landscape by phase related to the hyperparathyroidism market?
• What is the structure of clinical trial landscape by route of administration related to the hyperparathyroidism market?